ARCHIVES

GA101 Associated with Better PFS In Phase III Trial Versus Rituximab in CLL

This article is from The Cancer Letter archive.

Vol. 36 No. 7 | July 26, 2013

Download PDF Visit The Full Archive

Related Articles

In Brief: Chemical Carcinogenesis, Epidemiology Trail Viral Oncology In Budget Growth, Board Notes

November 7, 1980

Tumor Classification, Monoclonal Antibody Announcements Made

January 7, 1983

NCAB Asks Government To Take Steps Aimed at Reducing Health Hazards From Cigarettes

December 21, 1973

FDA Approves Avastin Combination For Late-Stage Cervical Cancer

August 29, 2014

In Brief: MSKCC Launches Molecular Oncology, Genomic Center

May 23, 2014

Phase III Regorafenib Trial Meets Endpoint Improving Progression-Free Survival

April 27, 2012